This phase 2, open-label, interventional study examined the safety and efficacy of pembrolizumab for patients with advanced, metastatic esophageal carcinoma that has progressed after 2 or more lines of systemic therapy.
https://ift.tt/2ScIHM9
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: June 2018 Source: Acta Biomaterialia, Volume 73 https://ift.tt/2kBbISt
-
http://bit.ly/2SylJiJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου